LMP2a-Specific Cytotoxic T-Lymphocytes Following CD45 Antibody for Lymphoma - Related Studies

LMP2a-Specific Cytotoxic T-Lymphocytes Following CD45 Antibody for Lymphoma (ACDAL)

This study is ongoing, but not recruiting participants.

Study NCT00082225. Last updated on December 20, 2007. Information provided by Baylor College of Medicine

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Lymphoma

2	More general conditions related to this trial
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type

3	Interventions listed in this trial
		CD45 antibodies
		EBV specific T cells

4	Additional drug interventions recognized in this trial
		Antibodies

5	More general drug interventions related to this trial
		Immunologic Factors
		Pharmacologic Actions
		Physiological Effects of Drugs

6	Sponsors listed in this trial
		Baylor College of Medicine
		The Methodist Hospital System
		Texas Children's Hospital
		Center for Cell and Gene Therapy